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ABSTRAcT
Background
In Malta smoking is widespread and associated with 
significant morbidity and mortality. Family doctors are 
well-placed to provide smoking cessation advice to their 
patients.
objective
The aim of this review is to assist family doctors in 
helping their patients quit smoking by informing them 
of evidence-based therapies.
method
The online Cochrane Database of Systematic Reviews 
within the Cochrane Library was searched for meta-
analyses and systematic reviews related to various 
smoking cessation interventions.
Results
Effective non-pharmacological interventions include 
individual counselling (face to face and over the 
telephone), text-messaging and group therapy. Smoking 
cessation medications that are successful and licensed 
comprise nicotine replacement therapy, bupropion 
and varenicline. Combining behavioural support and 
pharmacotherapy increases smoking cessation success.
conclusion
By following the 5As technique for smoking cessation 
based on evidence-based interventions, family doctors 
can have a considerable influence on the health of 
smokers by helping them to quit.
Key words
Evidence-based medicine; smoking cessation; family 
practice.
inTRoducTion
To ensure that clinical practice today provides effective 
health care, it should be based on evidence, with the 
latter being attained from scientific knowledge, research / 
audit findings and verified experiences (Kernohan, 
2006). In 1996, Sackett and colleagues defined evidence-
based medicine (EBM) as the conscientious, explicit 
and judicious use of current best evidence in making 
decisions about the care of individual patients. They went 
on to specify that successful EBM must comprise the best 
available external clinical evidence, clinical expertise and 
the involvement of patient choice, with best evidence 
provided by research that is clinically relevant and carried 
out using sound methodology (Sackett et al., 1996).
The practice of EBM thus involves a process of 
methodically locating, appraising, and making use of 
recent research findings in order to inform the taking 
of clinical decisions (Rosenberg and Donald, 1995). 
As the above may prove to be a laborious process for 
busy clinicians, the latter initially may refer to clinical 
guidelines drawn up by reputable organisations. If a 
guideline relevant to a certain clinical topic is not found, 
one may then search in online databases for systematic 
reviews (of quality studies with sound methodology) 
and/or meta-analyses (systematic reviews where data 
from quality studies are pooled and re-analysed as if one 
large study). (Sandholzer, 2004; Duke University, 2013)
BAcKGRound
In 2008, the European Health Interview Survey revealed 
that one third of the Maltese population had smoked 
daily or almost daily for at least one year. Males were 
approximately two times more likely than females to 
smoke daily, with occasional smokers being slightly 
more likely to be female than male. Passive smoking 
was a problem, with about a quarter of the respondents 
claiming to be somewhat exposed at home or in public. 
(Department of Health Information and Research, 2008)
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The average annual smoking-attributable mortality in 
Malta during 1999-2013 was estimated to be 396 deaths 
in males (42% from cancer, 40% due to cardiovascular 
disease and 18% from respiratory diseases) and 111 
deaths in females (37% due to cancer, 47% from 
cardiovascular disease and 16% due to respiratory 
diseases). (Department of Health Information and 
Research, 2014)
Therefore smoking is a widespread problem in Malta 
associated with significant morbidity and mortality. As 
patients see their family doctor four times a year on 
average, the latter has ample opportunities to practice 
preventive medicine in daily practice (McWhinney, 
1997). The promotion of health and well-being by 
applying the appropriate strategies in fact is one of the 
core competences of the family doctor (WONCA Europe, 
2005). The aim of this review thus is to assist family 
doctors in providing smoking cessation advice consisting 
of interventions that have been proved to work.
meTHod
As meta-analyses and systematic reviews are considered 
to be at the top of the hierarchy of study designs (Duke 
University, 2013), the online Cochrane Database of 
Systematic Reviews (CDSR) within the Cochrane Library 
(http://www.cochranelibrary.com) was searched 
for such designs related to various smoking cessation 
interventions. The Cochrane Library is maintained by a 
global independent network of researchers, professionals, 
patients, carers, and people interested in health, 
that gathers and summarises the best evidence from 
research to help make informed choices about treatment 
(Cochrane Library, 2016).
The CDSR systematic reviews are of randomised 
controlled trials (RCTs) or quasi-RCTs that test the efficacy 
of a drug or service where subjects are randomly allocated 
to receive one or other of alternative interventions. These 
reviews provide the risk ratio (RR), which gives the risk 
of a certain event happening in one group compared to 
the risk of the same event happening in another group, 
and the confidence interval (CI) within which results of 
a trial fall given a set probability (usually taken as 95%). 
ReSulTS
Eighty-two reviews related to ‘tobacco’ were found in 
the CDSR. Limiting this scrutiny to reviews of treatment 
modalities that can be used by family doctors to help 
otherwise-healthy adults in the community quit smoking, 
29 different interventions were identified and classified 
as follows for ease of reference: what doesn’t work, what 
makes no difference, what’s still uncertain, and what 
works.
1. What doesn’t Work
(a) non-pharmacological
As anxiolytics may assist anxiety associated with smoking, 
Hughes, Stead and Lancaster (2000) identified and 
reviewed 6 trials of the effect of anxiolytic drugs on 
smoking cessation for at least six months, but concluded 
that none showed strong evidence that they were effective.
Aversion therapy (such as rapid smoking) was 
reviewed by Hajek and Stead (2001), who, after 
identifying 25 relevant RCTs, concluded that there is 
insufficient evidence regarding its efficacy.
Hypnotherapy is supposed to help cessation by 
abating the craving to smoke or strengthening the 
determination to quit. However there is not enough 
evidence from 11 RCTs that hypnotherapy could be as 
effective as counselling in this regard (Barnes et al., 2010).
Although internet-based interventions are popular in 
this information technology age, when compared with 
self-help or usual care such interventions did not show 
consistent effects from 28 quasi/RCTs which were found 
to be at risk of bias (Civljak et al., 2013).
Acupuncture, acupressure, laser therapy and electrical 
stimulation have not been found to result in smoking 
cessation in the long term (for at least six months) from 
38 identified RCTs that only provided inconsistent and 
biased evidence (White et al., 2014).
Exercise programmes were not found to aid smoking 
cessation in the long term in an analysis of 20 trials 
by Ussher, Taylor and Faulkner (2014) who identified 
problems with study design, bias risks and study 
differences.
(b) Pharmacological
Nicobrevin, a product containing quinine, menthyl 
valerate, camphor and eucalyptus oil, had been promoted 
in the past as a smoking cessation aid. However, as no 
RCTs with long term follow-up were found, there is no 
evidence that it works (Stead and Lancaster, 2006).
Cannabinoid type 1 receptor antagonists 
(rimonabant and taranabant) restore the balance of 
the endocannabinoid system and were developed for 
the treatment of weight gain. Their mode of action was 
thought to perhaps be of help with smoking cessation, 
but a review of 3 RCTs concluded that, while rimonabant 
may increase the quit-rate by 50%, the evidence for 
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maintaining abstinence was uncertain. Both rimonabant 
and taranabant were withdrawn in 2008 due to their 
side-effects. (Cahill and Ussher, 2011)
Lobeline, an alkaloid produced from Indian tobacco 
leaves, was not found to help people stop smoking in a 
review by Stead and Hughes (2012), who could identify 
no adequate long-term trials.
Silver acetate, in the form of lozenges, gum and spray, 
produces an unpleasant metallic taste with smoking and 
thus was intended to help smokers to quit. However 
there is little evidence from 2 RCTs that it does result in 
cessation of smoking (Lancaster and Stead, 2012).
Nicotine vaccines have been designed to reduce 
effects of nicotine on the brain, with less reward from 
smoking. Four RCTs comparing nicotine vaccines to 
placebo showed that the former did not result in long-
term quitting (Hartmann-Boyce et al., 2012), with the 
authors of the analysis recommending that further trials 
of such vaccines are needed.
The long-acting opioid antagonist, naltrexone, was 
not found to assist smoking cessation in the long term 
from 8 trials with over 1200 participants (David et al., 
2013).
2. WHAT mAKeS no diffeRence
Studies comparing cutting down the number of cigarettes 
before quitting to the traditional abrupt quitting ‘cold 
turkey’ gave similar cessation rates (10 RCTs; number 
of participants [N] = 3760; RR= 0.94; 95% CI 0.79 to 
1.13), with the authors of the analysis (Lindson-Hawley, 
Aveyard and Hughes, 2012) advising that further studies 
needed to be carried out regarding the most effective 
method of cutting down before quitting.
3. What’s still uncertain
(a) non-pharmacological
Stage-based interventions for smoking cessation are 
based on the transtheoretical model of behaviour change 
that suggests that advice to smokers should be tailored 
to their stage of readiness to quit (precontemplation, 
contemplation, preparation, action and maintenance). 
From a review of the evidence from 41 stage-based trials 
of over 33,000 smokers measuring long-term quit rates, 
Cahill, Lancaster and Green (2010) found that “providing 
self-help or counselling support to smokers trying to quit 
is more effective than ‘usual care’ or simple observation. 
However, the extra value of fitting that support to the 
smoker’s stage of change is currently unclear”.
(b) Pharmacological
Mecamylamine (developed as an antihypertensive) is a 
nicotine antagonist and a review was carried out to see if 
it was of use as an aid to long-term smoking cessation. As 
only 2 small trails (N=128) were identified that suggested 
that mecamylamine in combination with nicotine may be 
superior to nicotine alone in helping smokers quit, the 
authors of the review recommended that larger studies 
are required (Lancaster and Stead, 1998).
Cytisine is a natural nicotine receptor partial agonist 
extracted from seeds of the Golden Rain acacia that 
aims to reduce withdrawal symptoms and smoking 
satisfaction. Two RCTs (N=937) found that it increases 
the chances of quitting, although absolute quit rates were 
modest at around 9% (Cahill et al., 2016).
Electronic cigarettes (ECs) are electronic devices that 
produce an inhalable aerosol through heating a liquid 
usually composed of propylene glycol and glycerol, with 
or without nicotine. Two RCTs (N=662) have found that 
ECs delivering nicotine help smokers to quit long-term 
compared with placebo ECs. However, confidence in 
the result is rated ‘low’ by standards developed by the 
Grading of Recommendations, Assessment, Development 
and Evaluations (GRADE) Working Group due to 
the small number of trials, low event rates and wide 
confidence intervals (Hartmann-Boyce et al., 2016).
4. WHAT WoRKS
(a) non-pharmacological interventions
The provision of printed self-help materials without any 
other contact was found by Hartmann-Boyce, Lancaster 
and Stead (2014) to increase quit rates compared to no 
intervention by about 20% from 11 RCTs with 13,241 
participants (RR 1.19; 95% CI 1.04 to 1.37).
Motivational interviewing (MI) is a style of counselling 
that is directive and patient-centred and aims to explore 
and overcome ambivalence about change in behaviour. A 
meta-analysis of 28 RCTs (N=16,803) of MI compared 
to usual care or brief advice showed an increase of about 
25% in quitting (RR 1.26; 95% CI 1.16 to 1.36). The 
authors (Lindson-Hawley, Thompson and Begh, 2015) 
however advised caution in interpreting these results 
because of differences between studies regarding their 
features and treatment delivery.
Individual counselling compared to minimal 
behavioural intervention in 22 quasi/RCTs (RR 1.39; 
95% CI 1.24 to 1.57) was found to increase the rate of 
quitting by 40% (Lancaster and Stead, 2005). Telephone 
counselling through calls to a helpline was also found 
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to increase the quit rate by 40% in a review of 9 quasi/
RCTs (N>24,000; RR 1.37; 95% CI 1.26 to 1.50) by 
Stead, Hartmann-Boyce et al. (2013). Mobile phone 
text-messaging in high-income countries increases long 
term quit rates by nearly 70% compared with control 
programmes according to 12 quasi/RCTs (N= 11,885; 
RR 1.67; 95% CI 1.46 to 1.90) reviewed by Whittaker 
et al. in 2016.
While brief advice intervention from a medical 
practitioner versus usual care or no advice increases 
the rate of quitting long term by nearly 70% (17 RCTs; 
RR 1.66; 95% CI 1.42 to 1.94) (Stead, Buitrago et al., 
2013), group therapy compared to self-help was found to 
double the chances of quitting from 13 RCTs (N=4375, 
RR 1.98; 95% CI 1.60 to 2.46) analysed by Stead and 
Lancaster (2005).
(b) Pharmacological interventions
Clonidine is a centrally-acting antihypertensive that was 
found to increase the rate of quitting by 60% from 6 
RCTs (RR 1.63; 95% CI 1.22 to 2.18). However, due to 
the limited number of studies with potential biases, and 
the drug’s important side-effects, its use for smoking 
cessation is limited (Gourlay, Stead and Benowitz, 2004).
Nicotine replacement therapy (NRT) aims to help the 
shift from smoking to quitting by replacing nicotine from 
cigarettes and thus decrease both the stimulus to smoke 
and the symptoms resulting from nicotine withdrawal. 
Such therapy is available in different forms (patch, gum, 
spray, inhaler and lozenges/tablets). Stead et al. (2012) 
established that NRT increase quit rates by 50-70% from 
117 RCTs with over 50,000 total participants (RR 1.60; 
95% CI 1.53 to 1.68).
The tricyclic antidepressant nortriptyline was found to 
double the chances of long term cessation, but from only 
6 RCTs with a total of 975 participants (RR 2.03; 95% 
CI 1.48 to 2.78). Due to adverse effects, nortriptyline is 
not licensed as a smoking cessation medication. There 
is more evidence available regarding bupropion, another 
antidepressant which inhibits norepinephrine-dopamine 
reuptake and is licensed also to treat smoking cessation. 
Forty-four RCTs (N=13,728; RR 1.62; 95% CI 1.49 
to 1.76) showed that it increases the rate of long term 
cessation by 60% (Hughes et al., 2014).
Varenicline, a synthetic nicotine receptor partial 
agonist, was specifically developed and approved as 
a smoking-cessation therapy in 2006. It has been 
ascertained from 27 RCTs (N=12,625) that varenicline 
increases the chances of successfully quitting long-term 
by two to three-fold compared with placebo (RR 2.24; 
95% CI 2.06 to 2.43) (Cahill et al., 2016).
(c) Pharmacological and behavioural 
interventions together
Adding behavioural support (face to face or by 
telephone) to pharmacotherapy may increase the chance 
of successful quitting by 10 - 25% as a result of pooling of 
results by Stead, Koilpillai and Lancaster (2015) from 47 
quasi/RCTs (N>18,000; RR 1.17; 95% CI 1.11 to 1.24).
Combined behavioural support (such as brief advice 
and counselling) and pharmacotherapy (e.g. NRT, 
varenicline and bupropion) increases smoking cessation 
success by over 80% compared to minimal interventions 
or usual care. This conclusion is based on high quality 
evidence from 52 quasi/RCTs (N=19,488) with a RR of 
1.83 and a 95% CI of 1.68 to 1.98 (Stead et al., 2016).
concluSion
The website BMJ Best Practice (http://bestpractice.bmj.
com) provides access to the latest research evidence, 
guidelines and expert opinion to aid diagnosis and 
treatment decisions. Regarding smoking cessation, it 
recommends the following 5-step technique for clinicians 
to follow (Best Practice, 2016):
• Ask: patients if they smoke;
• Advise: smokers on how quitting can help them 
achieve their goals;
• Assess: whether the patient is ready to attempt to 
stop and, if ready, how confident he/she is about 
success;
• Assist: if not ready to quit, inform the smoker 
that help is always available when he/she is 
ready; if willing to stop, provide a menu of 
pharmacotherapy / counselling;
• Arrange follow-up through a telephone counselling 
line, group or individual counselling, return visits 
and telephone calls.
Individual counselling and group therapy clinics 
are available in Malta from the Health Promotion Unit 
within Malta’s Ministry for Health that may be contacted 
as follows:
•	 website: https://health.gov.mt/en/health-
promotion/Pages/home.aspx;
•	 email: health.pro@gov.mt;
•	 telephones: 23266000 (main), 23266116 (tobacco 
support officer), 80073333 (quitline).
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Figure 1: Smoking cessation flowchart for the clinician
Preventive measures in tobacco control involves 
knowing which diseases are related to smoking, informing 
patients on the dangers of smoking and the benefits of 
quitting, and advising all patients who smoke to quit and 
how (Sammut, 2006). Giving up smoking is probably the 
biggest single thing smokers can do in their life to improve 
their health, and the intervention of family doctors in this 
respect (see Figure 1) will probably be the most important 
single influence they can have on the health of patients 
who smoke (Raw, 1988).
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